Opus Genetics reports Q3 net loss of $7.5M; pro forma cash $37M after Opus acquisition

Opus Genetics, Inc.

2024-Q3 EPS reported -$0.88 revenue$6,690,000

Net loss $7.5M ($0.29/share) vs net income $5.6M in Q3 2023; revenue $3.9M down from $11.9M.
Pro forma cash $37M post-merger with Opus Genetics; expects runway into 2026.
Acquisition of Opus Genetics closed Oct 22; issued 5.2M common shares and 14,145 Series A preferred.
Pipeline: four data readouts in 2025 including Phase 3 for Phentolamine in presbyopia and dim light.
Gene therapy candidate OPGx-LCA5 showed visual improvement in 3/3 adult patients; pediatric enrollment Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.